Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
STIMULATE-ICP
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Clinical trials == A number of different clinical trials will be run by STIMULATE-ICP, involving over 4,500 patients, and will include: * a new care pathway, with "enhanced rehabilitation" using the '[[Living with COVID Recovery Programme|Living with COVID Recovery]]' digital platform * a drug trial testing several different drugs, including: ** [[Famotidine]]/[[Loratidine]]: These [[anti-histamine]]s may reduce the "persistent inflammation" found in some Long COVID patients that is related to [[mast cell activation disorder|mast cell activation]] (MCAS or MCAD) and the release of histamine.<ref name="faq">{{Cite web|url=https://www.stimulate-icp.org/faq | title = FAQ | last = | first = | authorlink = | date = |website=STIMULATE-ICP|archive-url=|archive-date=|url-status=|access-date=2022-01-03}}</ref> **[[Rivaroxaban]]: "[[Microclots|Micro-clots]]" in the circulation of people with Long COVID may be reducing oxygen available to large muscles during [[exercise]]. The anti-clotting drug [[rivaroxaban]] may address the the [[post-exertional malaise]] found in some people with long COVID<ref name="faq" /> **[[Colchicine]]: This anti-inflammatory may reduce inflammation around the lining of the heart ([[pericarditis]]) and lungs ([[pleuritis]]). Colchicine is also used for pericarditis and may reduce [[chest pain]] and [[Dyspnea|breathlessness]] (dyspnea) in Long COVID.<ref name="faq" /> * a "usual care" pathway<ref name="overview" />
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs